Side-by-side comparison of AI visibility scores, market position, and capabilities
Greenwood Village CO YC W20 clinical biotech (NASDAQ: VRDN) with $636.6M cash; veligrotug BLA submission H2 2025 for thyroid eye disease competing with Tepezza; FcRn inhibitor platform with VRDN-003 and VRDN-006 in development.
Viridian Therapeutics is a Greenwood Village, Colorado-based clinical-stage biotechnology company — backed by Y Combinator (W20) and publicly traded on NASDAQ (VRDN) — developing FcRn inhibitor therapies for thyroid eye disease (TED) and other serious rare diseases driven by IgG autoantibodies. Maintaining $636.6 million in cash and short-term investments as of March 2025 (sufficient to fund operations into the second half of 2027), Viridian is advancing veligrotug (subcutaneous FcRn inhibitor, BLA submission expected H2 2025 for TED, MAA to EMA expected H1 2026), VRDN-003 (topline clinical data expected H1 2026), and VRDN-006 (proof-of-concept data expected Q3 2025), with $86.6 million in R&D expenses in Q2 2025 reflecting accelerated clinical development investment.
SF YC W24 AI support agent builder at 80% resolution time reduction and 71% ticket deflection; $500K from a16z/Greylock/YC/Netflix competing with Intercom Fin for customer support AI workflow automation.
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 additional investors — providing customer support teams with an AI agent builder that translates existing support processes and workflows into predictable, reliable AI automation, achieving 80% reduction in resolution time and 71% ticket deflection for deployed teams. Founded in 2023 and targeting customer support leaders at growth-stage software companies, Duckie enables support teams to deploy AI agents in minutes without engineering dependency.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.